Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3129)	6/8/2017 10:31:31 AM
From: tuck	Read Replies (3) \| Respond to of 3202

All the IDO inhibitors showed stable disease as the best response in P1. I'd guess that Genentech gave up because navoximod was behind the other two, and not sufficiently differentiated. Wonder if NLNK is a buy here. If we assume indoximod is roughly equivalent to epacadostat, the main problem for NLNK is having the dough to develop it broadly enough. Even if INCY got epacadostat back it would still have a much more robust development program. NLNK would either have to partner one of their drugs or raise cash (but they have ~$4/share, and are trading under $7.5 as I type, so it wouldn't be for a while; maybe they could reach inflection point first). Anyhow, bought a small trading position just now for $7.40. Bad news trade, would sell on a bounce for dinner money. Cheers, Tuck